Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study
Public ClinicalTrials.gov record NCT04606498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Blood Purification With Seraph® 100 Microbind® Affinity Blood Filter for the Treatment of Severe COVID-19: An Observational Study (PURIFY-OBS-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, observational study that will enroll 1) patients with severe COVID-19 who have agreed to undergo therapy with Seraph® 100 under the existing EUA; 2) patients (medical record data) that have been previously treated with the Seraph® 100 after the date of the EUA approval (17 April 2020), but before the date that the study is approved at the study site, and 3) a convenience sample of patients (medical record data) in a historical control group who were admitted to the ICU at participating sites with severe COVID-19 infection, meeting the EUA treatment criteria, but not treated with Seraph® 100 up to the time the PURIFY-OBS protocol is approved at the site
Study identification
- NCT ID
- NCT04606498
- Recruitment status
- Not listed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2020
- Primary completion
- Oct 30, 2022
- Completion
- Dec 31, 2022
- Last update posted
- Oct 31, 2022
2020 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| VA Greater Los Angeles Healthcare System | Los Angeles | California | 90073 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Advent Health | Orlando | Florida | 32803 | — |
| Southeast Georgia Health System - Brunswick Campus | Brunswick | Georgia | 31520 | — |
| Eisenhower Army Medical Center (EAMC) | Fort Gordon | Georgia | 30905 | — |
| Ian Stewart | Bethesda | Maryland | 20814 | — |
| Walter Reed National Military Medical Center | Bethesda | Maryland | 20814 | — |
| Forrest General Hospital | Hattiesburg | Mississippi | 39401 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Baylor Scott & White | Dallas | Texas | 75246 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Methodist Hospital | San Antonio | Texas | 78229 | — |
| University Of Texas Health San Antonio (UTHSA)- University Health | San Antonio | Texas | 78229 | — |
| Brooke Army Medical Center | San Antonio | Texas | 78234 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04606498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2022 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04606498 live on ClinicalTrials.gov.